JP4664984B2 - 腫瘍細胞で形成されるm−p53/p63、m−p53/p73およびm−p53/各イソ型タンパク質複合体を分解可能なペプチドおよび薬理学分野におけるその使用 - Google Patents
腫瘍細胞で形成されるm−p53/p63、m−p53/p73およびm−p53/各イソ型タンパク質複合体を分解可能なペプチドおよび薬理学分野におけるその使用 Download PDFInfo
- Publication number
- JP4664984B2 JP4664984B2 JP2007542144A JP2007542144A JP4664984B2 JP 4664984 B2 JP4664984 B2 JP 4664984B2 JP 2007542144 A JP2007542144 A JP 2007542144A JP 2007542144 A JP2007542144 A JP 2007542144A JP 4664984 B2 JP4664984 B2 JP 4664984B2
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- tumor
- protein
- peptides
- protein complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
1) FQQSSTAKSATW
2) PLLKKLYCQI
3) CPIQIKVSTPPP
4) IRAMPVYKKAEH
5) VVKRCPNHE
6) GQRDFNEGQSAPA
7) IRVEGNNLS
8) DDPVTGRQSVVV
9) GQVGTEFTTIL
10) MNCNSSCVGGMNRR
11) IIITLEMRDGQ
12) RRSFEGRICAC
13) DRKADEDHYR
本発明のペプチドがm-p53とp73との相互作用を破壊する能力を評価するため、細胞モデルとして、p73および特定形状のm-p53(p53-HIS 175)を十分量内在するSKBr3(ヒト乳ガン)細胞を用いて共沈実験を行った。
9個のアミノ酸で形成されるペプチドであり、うち3つ(VVP)は疎水性、3つは塩基性(KRH)、1つは酸性(E)、2つは極性(CN)である。
13個のアミノ酸で形成されるペプチドであり、うち4つ(FAPA)は疎水性、1つは塩基性(R)、2つは酸性(DE)、6つは極性(GQNGQS)である。
9個のアミノ酸で形成されるペプチドであり、うち3つ(IVL)は疎水性、1つは塩基性(R)、1つは酸性(E)、4つは極性(GNNS)である。
12個のアミノ酸で形成されるペプチドであり、うち5つ(PVVVV)は疎水性、1つは塩基性(R)、2つは酸性(DD)、4つは極性(TGQS)である。
Claims (6)
- 腫瘍細胞の核内で形成されるm-p53/p63、m-p53/p73および m-p53/p-イソ型タンパク質複合体を分解させることができるFQQSSTAKSATW、PLLKKLYCQI、CPIQIKVSTPPP、IRAMPVYKKAEH、VVKRCPNHE、GQRDFNEGQSAPA、IRVEGNNLS、DDPVTGRQSVVV、GQVGTEFTTIL、MNCNSSCVGGMNRR、IIITLEMRDGQ、RRSFEGRICAおよびDRKADEDHYRを含む群から選択される、腫瘍サプレッサー用ペプチド。
- VVKRCPNHE、GQRDFNEGQSAPA、IRVEGNNLSおよびDDPVTGRQSVVVを含む群から選択される、請求項1に記載のペプチド。
- ヒト腫瘍治療用の抗腫瘍剤調製への、請求項1または2に記載のペプチドの使用。
- 細胞レベルで前記ヒト腫瘍にm-p53/p63、m-p53/p73および/またはm-p53/p-イソ型タンパク質複合体がみられる、請求項3に記載の使用。
- 前記腫瘍が肺腫瘍である、請求項4に記載の使用。
- m-p53/p63、m-p53/p73 および/またはm-p53/p-イソ型タンパク質複合体を分解させる方法であって、前記複合体がin vitroでヒト腫瘍の腫瘍細胞の核内で形成されており、
−m-p53/p63、m-p53/p73および/またはm-p53/p-イソ型タンパク質複合体を含有する腫瘍細胞系を、培養液に準備する工程;
−請求項1または2に記載のペプチドのうち少なくとも1種を前記培養液に添加する工程;
−ペプチド処理細胞を溶解、共沈させる工程;
−前記タンパク質複合体が分解されたことを確認する工程
を含む方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT002227A ITMI20042227A1 (it) | 2004-11-19 | 2004-11-19 | Peptide in grado di rompere il complesso m-p53-p63, m-p53-p73 e m-p53-relative proteine isoformi formatosi nelle cellule tumorali e relativi impieghi in campo farmacologico |
PCT/IB2005/003395 WO2006054138A1 (en) | 2004-11-19 | 2005-11-14 | PEPTIDE ABLE TO BREAK THE m-p53/p63, m-p53/ p73 AND m-p53/RESPECTIVE ISOFORM PROTEINS COMPLEX FORMED IN THE TUMOR CELLS AND USES THEREOF IN THE PHARMACOLOGICAL FIELD |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008520641A JP2008520641A (ja) | 2008-06-19 |
JP4664984B2 true JP4664984B2 (ja) | 2011-04-06 |
Family
ID=36051431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007542144A Expired - Fee Related JP4664984B2 (ja) | 2004-11-19 | 2005-11-14 | 腫瘍細胞で形成されるm−p53/p63、m−p53/p73およびm−p53/各イソ型タンパク質複合体を分解可能なペプチドおよび薬理学分野におけるその使用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US7939624B2 (ja) |
EP (1) | EP1812467B1 (ja) |
JP (1) | JP4664984B2 (ja) |
AT (1) | ATE394421T1 (ja) |
DE (1) | DE602005006607D1 (ja) |
IL (1) | IL183045A (ja) |
IT (1) | ITMI20042227A1 (ja) |
WO (1) | WO2006054138A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1393985B1 (it) * | 2009-05-11 | 2012-05-17 | Ist Fisioterap Ospitalroma | Peptide capace di disassemblare i complessi proteici fra la proteina p53 mutata his 273 e la proteina oncosoppressiva p73 in cellule tumorali e suoi usi in campo medico. |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998051350A1 (en) * | 1997-05-12 | 1998-11-19 | Dana-Farber Cancer Institute | Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies |
WO1999066946A1 (en) * | 1998-06-24 | 1999-12-29 | Trustees Of The University Of Pennsylvania | Compositions and methods for inducing apoptosis in e6-expressing cells |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2744455B1 (fr) * | 1996-02-02 | 1998-04-24 | Sanofi Sa | Nouvelles sequences d'acides nucleiques de la famille des facteurs suppresseurs de tumeurs, produits d'expression correspondants et leurs applications |
AU3208699A (en) * | 1998-03-27 | 1999-10-18 | Johns Hopkins University, The | P40 protein acts as an oncogene |
AU2002327945A1 (en) * | 2001-09-17 | 2003-04-01 | Eirx Therapeutics Limited | Human delta-n p73 molecules and uses thereof |
-
2004
- 2004-11-19 IT IT002227A patent/ITMI20042227A1/it unknown
-
2005
- 2005-11-14 JP JP2007542144A patent/JP4664984B2/ja not_active Expired - Fee Related
- 2005-11-14 WO PCT/IB2005/003395 patent/WO2006054138A1/en active IP Right Grant
- 2005-11-14 DE DE602005006607T patent/DE602005006607D1/de active Active
- 2005-11-14 US US11/719,169 patent/US7939624B2/en not_active Expired - Fee Related
- 2005-11-14 EP EP05818849A patent/EP1812467B1/en not_active Not-in-force
- 2005-11-14 AT AT05818849T patent/ATE394421T1/de not_active IP Right Cessation
-
2007
- 2007-05-07 IL IL183045A patent/IL183045A/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998051350A1 (en) * | 1997-05-12 | 1998-11-19 | Dana-Farber Cancer Institute | Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies |
WO1999066946A1 (en) * | 1998-06-24 | 1999-12-29 | Trustees Of The University Of Pennsylvania | Compositions and methods for inducing apoptosis in e6-expressing cells |
Also Published As
Publication number | Publication date |
---|---|
EP1812467B1 (en) | 2008-05-07 |
DE602005006607D1 (de) | 2008-06-19 |
ITMI20042227A1 (it) | 2005-02-19 |
US7939624B2 (en) | 2011-05-10 |
ATE394421T1 (de) | 2008-05-15 |
IL183045A (en) | 2011-06-30 |
US20090181418A1 (en) | 2009-07-16 |
IL183045A0 (en) | 2007-09-20 |
JP2008520641A (ja) | 2008-06-19 |
WO2006054138A1 (en) | 2006-05-26 |
EP1812467A1 (en) | 2007-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gunster et al. | Identification and characterization of interactions between the vertebrate polycomb-group protein BMI1 and human homologs of polyhomeotic | |
KR102302392B1 (ko) | 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물 | |
US7279554B2 (en) | Notch receptor ligands and uses thereof | |
EP1220905A2 (en) | Composition and methods for the treatment of immune related diseases | |
US5821082A (en) | Anti-proliferation domain of a human Bcl-2 and DNA encoding the same | |
JP2006122049A (ja) | Gapタンパク質sh3ドメインに結合可能なペプチド、それをコードするヌクレオチド配列ならびにその製造法および使用 | |
WO2000073452A2 (en) | Compositions and methods for the treatment of immune related diseases | |
Yin et al. | Evidence that HAX-1 is an interleukin-1α N-terminal binding protein | |
US20200071407A1 (en) | Inhibitors of prototypic galectin dimerization and uses thereof | |
WO1995034650A9 (en) | Mn gene and protein | |
US5759803A (en) | Recombinant retinoblastoma-associated protein 1 (E2F-1) polypeptides and cDNA | |
EP2268658B1 (en) | Peptides and aptamers thereof as specific modulators of mutant p53 function | |
JP4664984B2 (ja) | 腫瘍細胞で形成されるm−p53/p63、m−p53/p73およびm−p53/各イソ型タンパク質複合体を分解可能なペプチドおよび薬理学分野におけるその使用 | |
Santiago et al. | Extracellular signal-regulated kinase-1 phosphorylates early growth response-1 at serine 26 | |
JP4201712B2 (ja) | Gip、グッドパスチャー抗原結合タンパク質と相互作用する転写因子活性を備えたポリペプチドのファミリー | |
EP1206487A2 (en) | Notch receptor ligands and uses thereof | |
Coffer et al. | Divalent metal ions induce conformational change in pure, human wild-type p53 tumor suppressor protein | |
WO2000022142A2 (en) | Cell signaling polypeptides and nucleic acids | |
Tsuchiya et al. | Renal cell carcinoma-and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones | |
KR100279302B1 (ko) | 티로신인산화효소의sh2영역에결합하는어댑터단백질유전자의선별방법 | |
Zhan et al. | Assembly of mTORC3 involves binding of ETV7 to two separate sequences in the mTOR kinase domain | |
Cai et al. | Identification of HSP47 Binding Site on Native Collagen and Its Implications for the Development of HSP47 Inhibitors. Biomolecules 2021, 11, 983 | |
KR101302195B1 (ko) | Prdm 10의 c 말단 부위 단백질에 대한 항체 및 그 제조방법 | |
US20120258482A1 (en) | Pcna methyltransferase | |
KR101302196B1 (ko) | Prdm 10의 n 말단 부위 단백질에 대한 항체 및 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080801 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101221 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110107 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140114 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |